4:54 PM · 17 April 2024

Sage Therapeutics craters over 20% on study results

Sage
Stocks
SAGE.US, Sage Therapeutics Inc
-
-

Shares of Sage Therapeutics (SAGE.US) are plunging today. Company is one of the worst performing Wall Street stocks today, plunging over 20% at press time. The move lower was triggered after company released results of mid-stage study of its experimental dalzanemdor treatment for Parkinson's disease. Company said that the study failed to meet its main goal and did not show any statistically significant differences between the treatment and placebo. 

Sage Therapeutics said that it does not plan any further development of dalzanemdor treatment for Parkinson's disease. Results of the Phase 2 studies in Huntington's and Alzheimer's diseases are expected in the later part of 2024.

Taking a look at Sage Therapeutics (SAGE.US) chart at D1 interval, we can see that the stock has recently plunged below the $16.50 support zone and continues to move lower. A massive plunge today pushed the stock below $11 per share for the first time in history. However, a part of the drop has been recovered and the stock trades off the daily lows now.

Source: xStation5

3 October 2025, 6:47 PM

Daily Summary: US2000 leads on Wall Street📈Crypto and metals up, US dollar down

3 October 2025, 4:25 PM

Coinbase shares above important resistance zone🔔

3 October 2025, 4:11 PM

US500 hits new all-time high📈Applied Materials loses, RareEarth USA surges on US deal rumors

3 October 2025, 12:46 PM

DE40: Europe looking for direction amid mixed PMI reports

Join over 1 700 000 XTB Group Clients from around the world

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits